References: 37 Key points 1. "Pathogenic" or "likely pathogenic" classified variants in known genes were discovered in 46% of index cases with an inherited thrombocytopenia of unknown aetiology.
Introduction
Inherited thrombocytopenias (IT) are a heterogeneous group of disorders characterised by platelet counts of less than 150x10 9 /L in whole blood. Platelet counts are considered normal when maintained at levels between 150-450x10 9 /L. This is achieved by homeostatic processes controlling platelet production (thrombopoiesis), platelet senescence and platelet consumption/destruction.
Pathogenic mutations can result in a disruption of these balanced processes causing inherited thrombocytopenia. However, the clinical manifestation of bleeding is often dependent on both a decreased platelet count and a qualitative or acquired platelet defect. Clinical complications can vary dramatically from severe and potentially life threatening bleeding to being asymptomatic. This variation is noted amongst individuals shown to have the same underlying genetic causes of disease, suggesting that bleeding risk and phenotype is a complex trait (1).
The average incidence of IT is estimated to be approximately 270 cases per 1 million live births (2). To date there are 27 individual IT disorders with known causative mutations registered within OMIM, although 33 disease causing genes have been described (3).
Genetic studies have played a major role in the diagnosis and progressive understanding of IT. The genes implicated in the disease encode proteins that vary widely in function and include transcription factors (ETV6, FLI1, GATA1, GFI1B and RUNX1) and proteins involved in cytoskeleton rearrangement and organisation (ACTN1, FLNA, GP1BA, GP1BB, GP9, TUBB1 and WAS) . However, some protein functions currently remain unknown (SLFN14 and GNE) (4-9). Although our knowledge of the causes of IT continues to grow, presently a genetic diagnosis is only reported in approximately 50% of individuals (10-12).
Previously, genetic investigation into IT has focused on candidate gene sequencing and individual cases of whole exome sequencing (WES) when a causative gene is not obvious (9) . With 50% of patients currently undiagnosed, a change in the way we approach genetic diagnosis is necessary. Here we present the first large scale WES only approach to patients with suspected IT. We demonstrate its application in determining possible genetic origins of IT including identification of variants in novel candidate causative genes. We combine this with an approach implemented by the Genotyping and Phenotyping of Platelets (GAPP) study, which combines WES analysis with extensive platelet phenotyping to create a complete method of diagnosis and gene discovery in this subset of patients.
Methods

Study approval
The UK-GAPP study was approved by the National Research Ethics Service Committee of West Midlands-Edgbaston (REC reference: 06/MRE07/36) and participants gave written informed consent in accordance with the Declaration of Helsinki. This study was registered at www.isrctn.org as #ISRCTN 77951167. The GAPP study is included in the National Institute of Health Research Non-Malignant Haematology study portfolio (ID9858).
Platelet counts, morphology and white blood cell counts
Patient samples were compared to the range of healthy volunteers for the specific method of morphology used. Platelet counts for light transmission aggregometry (LTA) and flow cytometry analysis as well as mean platelet volume (MPV) in platelet rich plasma (PRP) were originally measured using the Beckman coulter counter (n=44). Subsequently, platelet counts, morphology and white blood cell counts in whole blood were measured using the Sysmex XN-1000 (n=11). The PLT-F channel was used to determine platelet counts in whole blood and the immature platelet fraction (IPF). MPV was determined from the impedance PLT-I channel. White blood cell counts were determined using the Sysmex XN-DIFF channel. All samples were tested against a normal range which was established by measuring the counts for 40 healthy individuals using the Sysmex XN-1000.
Platelet preparation and platelet function testing
Platelet function was assessed by light transmission aggregometry, including lumiaggregometry, for samples having platelet counts in PRP of >1x10 8 /mL (n=13).
An in-house flow-cytometry assay was developed to assess platelet function in patients having platelet counts in PRP <1x10 8 /mL (n=22). Platelets from individuals with borderline platelet counts in PRP between 1.0 and 1.5x10 8 /mL were assessed using both assays (n=16).
Aggregometry was performed as previously described (13, 14) . For flow cytometry, resting surface levels of CD42b, CD41 and GPVI were assessed. PRP was then stimulated with ADP (3 and 30 µM), CRP (0.3 and 3µg/ml) and PAR-1 peptide (10 and 100 µM). Membrane expression of P-selectin (FITC-conjugated mouse antihuman CD62P antibody, BD Pharmingen), a marker of platelet alpha granule release, as well as fluorescent fibrinogen binding (marker of integrin activation) was assessed by flow cytometry on an Accuri C6 flow cytometer. Incubation took place at 37ºC for 2 min and was terminated by adding a fivefold excess of ice cold PBS.
Whole exome sequencing
WES and bioinformatics analysis was performed as described previously (8, 15, 16) ( Figure 1 ).
Pathogenicity of variants was determined and called using the consensus guidelines as set out by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG guidelines) (17). Segregation was determined by Sanger sequencing of candidate variants in both affected and unaffected family members, when available, and classification was adapted appropriately for the specific study and small sample size.
Sanger sequencing
To verify candidate mutations and examine their segregation among family members
Sanger sequencing was performed using standard methods on an ABI 3730 automated sequencer as described previously (8).
Results
Patient recruitment
To date, 55 patients with a suspected IT or sustained reduced platelet counts have been enrolled from 25 UK Haemophilia Care Centres and investigated as part of the GAPP study. Before enrolment in the study, all patients underwent clinical and genetic work-up to exclude known platelet disorders (including Bernard-Soulier
Syndrome and MYH9-related disorders, analysed initially by blood film), idiopathic thrombocytopenic purpura (ITP) and other non-platelet disorders including von Willebrand disease and inherited coagulation factor deficiencies. Patient bleeding phenotypes are displayed in Table 1 . WES was performed on genomic DNA from all patients, including 37 index cases, all of whom met the study's entry criteria. All patients, excluding F35.I and F35.II, were of white British or mixed British ethnicity.
All results following platelet function testing and WES were reported back to the referring haematological consultants to aid in genetic counselling and disease management.
Platelet counts, morphology and function testing
Patients were recruited with a platelet count in whole blood, at the time of enrolment, of less than 150x10 9 /L. Patients having platelet counts in the range of 150-200x10 9 /L remained enrolled in the study if they showed a similar phenotype to related affected family members and a platelet count below 150x10 9 /L had been observed prior to In total 28 variants were noted in 14 genes previously known to cause IT ( On average, less than one novel variant was expected to be observed in the known IT causing genes in which variants were observed. The number of variants occurring also exceeds the expected number when extending the analysis to cover variants with a MAF of <0.01.
Of the 37 index patients, four presented with two candidate variations in known disease linked genes, which in one case were present in the same gene. These Platelets from the majority of these patients (10/13) demonstrated a reduction in ATP secretion and, in keeping with previous reports, several of these patients displayed additional clinical features. Variations in RUNX1 are associated with a propensity to myelodysplastic syndrome and acute myeloid leukaemia (AML). To date, haematological malignancies have not been reported in any patients; however, the brother of F16.1 did have a history of AML but was unavailable for testing. 
Potentially damaging variants in novel candidate genes
Novel missense candidate variants in PADI2 and TTF2
A large kindred with three affected individuals and four unaffected related individuals were recruited to the study. A mild thrombocytopenia was observed within the family with platelet counts ranging from 80-186x10 9 /L in the three affected individuals. All three affected individuals presented with a normal platelet size (7.9-8.6fL) and a mild (Table 3 ) and are currently classified as "uncertain significance".
Discussion
Here we present the first large scale application of WES analysis to patients with inherited bleeding diatheses presenting with thrombocytopenia of unknown aetiology.
Platelet counts and phenotypic presentation vary among our patients considerably which is consistent with the variability observed in the spectrum of IT. However, the majority of patients (73%) were noted to have a secondary qualitative defect in platelet function which may explain the disproportionate bleeding when compared to the patient's platelet counts. A lack of consistency was noted in families 13 and 30
where affected individuals are observed both with and without defects in platelet function. Clinical complications are shared among the affected family members so this most likely represents limitations in the sensitivity of platelet function testing or intra-familial variability.
Overall, when considering pathogenicity WES analysis revealed 46% of index cases (17/37) to have a positive prediction of pathogenicity (classified "pathogenic" or "likely pathogenic" in a gene consistent with the patients phenotype and zygosity consistent with expected inheritance). Twenty-two percent of the index cases (8/37)
were of uncertain/possible pathogenicity (results classified of "uncertain significance"
in known IT causing genes). The remaining 32% of index cases (12/37) had a negative prediction of pathogenicity (no convincing variants identified in known causing genes). WES is not without its limitations and like with any genetic analysis all variants must be functionally confirmed as deleterious to the coded protein.
However, our positive variant discovery rate is comparable to or exceeds previous large scale WES clinical multicentre studies of Mendelian disorders (22, 23). showed a slight increase in MPV; however this was not at the magnitude of giant platelets normally attributed to this group of disorders and only patient F9.I showed any secondary syndromic symptoms with the individual suffering from congenital cataracts.
One attribute of excluding patients with known variants in GP1BA, GP1BB, MYH9
and potentially GP9 is the discovery of a relatively large percentage of individuals analysed (24% of index cases) with variants in RUNX1 as a primary likely cause of disease. With the exception of one predicted loss of function variant, the variants present within RUNX1 are currently classified as either "likely pathogenic" or of "uncertain significance" and need functional confirmation to be disease causing.
However, the presence of these variants in a large number of individuals with an often shared secondary functional defect in secretion does suggest the prevalence of RUNX1 variants may be higher than previously thought. This raises the question whether it should be considered as clinically significant as BSS and MYH9-related disorders and be primarily screened for genetically upon initial diagnosis with IT. ( 1 6 ) : /L (normal range to 2SD 147-327x10 9 /L, n=40). Average MPV = 10fL
(mean normal range to 2SD 7.8-12.69fL, n=40). IPF was available for 11 patients and varied between 1.8-87% (normal range 1.3-10.8%, n=40). Patients with an observed macro and micro thrombocytopenia are denoted by a + and -, respectively, following their most recent analysed MPV. Secondary qualitative defects are abbreviated to the following; (Gi) -reduction in response upon ADP stimulation indicating a possible defect in the Gi pathway, (GPVI) -reduction in surface GPVI quantity. Bleeding diathesis of each individual is summarised under bleeding phenotype. Table 2 Results of whole exome sequencing analysis of 55 patients with inherited thrombocytopenia showing variants in known thrombocytopenia causing genes. 68% of individuals have a predicted genetic aetiology in a previously IT associated gene. When a variant has been previously observed it is annotated in the prevalence column with the database it is observed in. The ACMG consensus guideline results are also displayed in the final column (17). Table 3 Potentially damaging variants in novel candidate genes. When a variant has been previously observed it is annotated in the prevalence column with the database it is observed in. PhyloP scores vary between -14 and +6 and measure conservation at each individual base, sites predicted to be conserved are assigned a positive score, fast evolving sites are assigned a negative score. Mutationtaster uses a Beyes classifier to predict the effect of a mutation from a feed a classifiers. SIFT damaging prediction score= <0.05. Provean deleterious score = <-2.5.
PolyPhen-2 predictions are appraised qualitatively as benign or damaging. The ACMG consensus guidelines, including supporting evidence, are also shown. 
